I am a
Home I AM A Search Login

Papers of the Week

Papers: 1 Oct 2022 - 7 Oct 2022

Pharmacology/Drug Development

2022 Sep 29

J Pain

Minocycline prevents the development of key features of inflammation and pain in DSS-induced colitis in mice.


Vezza T, Molina-Tijeras J A, González-Cano R, Rodríguez-Nogales A, García F, Gálvez J, Cobos EJ
J Pain. 2022 Sep 29.
PMID: 36183969.


Abdominal pain is a common feature in IBD patients, and greatly compromises their quality of life. Therefore, the identification of new therapeutic tools to reduce visceral pain is one of the main goals for IBD therapy. Minocycline, a broad-spectrum tetracycline antibiotic, has gained attention in the scientific community because of its immunomodulatory and anti-inflammatory properties. The aim of this study was to evaluate the potential of this antibiotic as a therapy for the management of visceral pain in dextran sodium sulfate (DSS)-induced colitis in mice. Preemptive treatment with minocycline markedly reduced histological features of intestinal inflammation and the expression of inflammatory markers (Tlr4, Tnfα, Il1ß, Ptgs2, Inos, Cxcl2 and Icam1), and attenuated the decrease of markers of epithelial integrity (Tjp1, Ocln, Muc2 and Muc3). In fact, minocycline restored normal epithelial permeability in colitic mice. Treatment with the antibiotic also reversed the changes in the gut microbiota profile induced by colitis. All these ameliorative effects of minocycline on both inflammation and dysbiosis correlated with a decrease in ongoing pain and referred hyperalgesia, and with the improvement of physical activity induced by the antibiotic in colitic mice. Minocycline might constitute a new therapeutic approach for the treatment of IBD-induced pain. Perspective: This study found that the intestinal anti-inflammatory effects of minocycline ameliorate DSS-associated pain in mice. Therefore, minocycline might constitute a novel therapeutic strategy for the treatment of IBD-induced pain.